Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 3, 2000, Pages 305-313

  Klinkhardt, Ute ^a,b   Kirchmaier, Carl M ^a,b   Westrup, Dagmar ^a,b   Graff, Jochen ^a,b   Mahnel, Rene ^a,b   Breddin, Hans Klaus ^a,b   Harder, Sebastian ^a,b,c  

^a GOETHE UNIVERSITY   (Germany)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 [4 (AMINOIMINOMETHYL)PHENYL] 2 THIAZOLYL](1 CARBOXYMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; PADGEM PROTEIN;

ADULT; ARTICLE; BLEEDING TIME; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; TURBIDIMETRY;

EID: 0034067611     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.104613     Document Type: Article

References (32)

1. 1. Califf RM. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
2. 2. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996;78:35-40.
3. 3. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997;100(11 suppl):S57-S60.
4. 4. Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2-methylthio ADP to rat platelets: effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994;269: 772-7.
5. 5. Coukell AJ, Markham A. Clopidogrel. Drugs 1997;54: 745-50.
6. 6. Berger PB, Bell MR, Hasdai D, Grill DE, Melby S, Holmes DR Jr. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circulation 1999;99:248-53.
7. 7. Savi P, Badorc A, Lalé A, Bordes MF, Bornia J, Labouret C, et al. SR 121787, a new orally active fibrinogen receptor antagonist. Thromb Haemost 1998;80:469-76.
8. 8. Theroux P. Oral inhibitors of platelet membrane receptor glycoprotein IIb/IIIa in clinical cardiology: issues and opportunities. Am Heart J 1998;135:S107-12.
9. 9. Herman AG. Rationale for the combination of anti-aggregating drugs. Thromb Res 1998;15;92(1 suppl 1):S17-21.
10. 10. Gregorini L, Marco J, Fajadet J, Bernies M, Cassagneau B, Brunel P, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 1997;29:13-20.
11. 11. Farell TP, Hayes KB, Sobel BE, Schneider DJ. The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine. Am J Cardiol 1999;83:770-4.
12. 12. Frederick LG, Suleymanov OD, King LW, Salyers AK, Nicholson NS, Feigen LP. The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. Circulation 1996;93:129-34.
13. 13. Freed MI, Boike S, Zariffa N, Jorkasky DK. Effects of ASA on inhibition of ex vivo in vitro platelet aggregation and secretion by SKF 107260, a novel IIb/IIIa receptor antagonist. Thromb Haemost 1994;72:622-6.
14. 14. Umemura K, Kondo K, Ikeda Y, Nakashima M. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. Thromb Haemost 1997;78:1381-4.
15. 15. Klinkhardt U, Kirchmaier CM, Hildt M, Breddin HK, Westrup D, Mahnel R, et al. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abciximab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters. Thromb Res 2000;97:209-11.
16. 16. Born GVR. Quantitative investigations into the aggregation of blood platelets. J Physiol 1962;162:67-8.
17. 17. Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med 1994;123:728-40.
18. 18. Herbert JM, Dol F, Bernat A, Falotico R, Lalé A, Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998;80:512-8.
19. 19. Makkar RR, Eigler NL, Kaul S, Frimerman A, Nakamura M, Shah PK, et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998;19: 1538-46.
20. 20. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665-71.
21. 21. Coller BS. Monitoring platelet GPIIb/IIIa antagonist therapy. Circulation 1997;96:3828-32.
22. 22. Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997;96:1117-21.
23. 23. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996;76:939-43.
24. 24. Rupprecht HJ, Darius H, Borkowski U, Voigtländer T, Nowak B, Genth S, et al. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998;97:1046-52.
25. 25. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979;254:5357-63.
26. 26. Gachet C, Stierlé S, Cazenave JP, Ohlmann P, Lanza F, Bouloux C, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat. Biochem Pharmacol 1990;40:229-38.
27. 27. Hardisty RM, Fowling MJ, Nokes TJ. The action of ticlopidine on human platelets: studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost 1990;64:150-5.
28. 28. Schini-Kerth V, Kirchmaier CM, Bassus S, Busse R. Aggregating human platelets stimulate the expression of thrombin receptors in cultured VSMC via the release of transforming growth factor β1 and platelet derived growth factor AB. Circulation 1997;96:3888-96.
29. 29. Neumann FJ, Gawaz M, Dickfeld T, Wehinger A, Walter H, Blasini R, et al. Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol 1997:29:1515-9.
30. 30. Chronos NAF, Wilson DJ, Janes SL, Hutton RA, Buller NP, Goodall AH. Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of α-granules or lysosomes from, human platelets. Clin Sci 1994;87:575-80.
31. 31. Tsao PW, Forsythe MS, Mousa SA. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb Res 1997;88:137-46.
32. 32. Byrne A, Moran N, Maher M, Walsh N, Crean P, Fitzgerald DJ. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. Arterioscler Thromb Vasc Biol 1997;17:3224-9.